Public Policy Resources

Pharmacogenomic (PGx) Testing: Tests Guide Appropriate Drug Selection and Dosing

August 2, 2022

Pharmacogenomic (PGx) testing (also known as pharmacogenomic biomarker testing) is a component of precision medicine that involves examining a patient’s inherited genes to detect variations that may impact the way a drug is broken down, absorbed and used within the body. Sometimes these variations can impact the safety and effectiveness of treatment. The same treatment given to patients with the same disease can produce different responses based on each person's inherited genes.

PDF icon Download Pharmacogenomic (PGx) Testing Factsheet

Related Resources

Survivor Views: One in Ten Impacted by Recent Drug Shortages

October 19, 2023

The nation’s drug shortage crisis continues to affect cancer patients and survivors with 1 in every 10 (10%) reporting impacts to care, a majority of whom have had difficulties finding substitute medications (68%) and cited treatment delays (59%).

Read more

Payer Coverage Policies of Tumor Biomarker and Pharmacogenomic Testing

March 24, 2023

Biomarker testing is key to unlocking precision medicine. However, coverage for guideline-recommended biomarker tests is not universal and can be a barrier to cancer patients accessing treatments that can lead to improved survival and quality of life.  

Read more